Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
about
Aldosterone antagonists for preventing the progression of chronic kidney diseaseAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseaseAldosterone antagonists for preventing the progression of chronic kidney diseaseAn evolving story of angiotensin-II-forming pathways in rodents and humansRisks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic ReviewMeta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failureRationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.The systematic guideline review: method, rationale, and test on chronic heart failure.Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate.Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases.Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.Combining angiotensin receptor blockers with ACE inhibitors in elderly patientsThe effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysisRenin-angiotensin-aldosterone system blockade for cardiovascular diseases: current statusFailure or success of electronic search strategies to identify adverse effects data.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyThe safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis.The therapeutic role of RAS blockade in chronic heart failure.Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskCardiac and vascular protection: the potential of ONTARGET.The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studiesCurrent possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.You can do more to slow the progression of heart failure.Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises.Nutrition and heart failure: impact of drug therapies and management strategies.Management of hypertension in chronic heart failure.Managing cardiovascular and renal risk: the potential of direct renin inhibition.Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.Recent changes in the landscape of combination RAS blockade.Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question.Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.Chronic heart failure: current evidence, challenges to therapy, and future directions.Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis.The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population.Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events.The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.
P2860
Q24194979-0E091528-7930-4FD5-B146-558F8E033355Q24235834-00D7FCAF-FD10-40E5-9677-AC262585F311Q24239909-52D2A033-298F-4AF5-9DF0-F19C88EE9406Q26830036-B5FBA451-19FC-4D46-AD93-14867245F1E1Q27026079-33FF0761-3716-4816-9E1A-690047445FCEQ28748219-826522FC-0DFD-4413-9CE2-D499D3CEF2ACQ30452640-092F30D3-C01A-4F05-A9A0-79E73FA8B554Q33414957-822F3B4F-980A-415F-810C-6A6859F50E18Q33441898-23C87F39-68F3-49E9-95F6-CA9B4702C655Q33554921-E2CA53D0-0D2A-47AC-B7DD-987060BC8F4CQ33756874-B3F382B1-B79A-44EF-845C-25BBAD748EC5Q33783689-ED13BE0F-6E70-482C-8081-0043F51E988BQ33830694-032C0D16-D2CB-4024-85EB-D0FE451C54D8Q34122611-195CDF0D-0E30-4C0A-840B-958344D06F22Q34124779-56C966FE-4F8E-4478-AAD1-4727E836B7ACQ34238325-623BD8B0-D821-405F-826F-CCF656CA0462Q34386587-DEF30829-4DF5-4303-B4E9-2C676C1B09E4Q34765075-F624A7CE-B4FA-4D73-A65D-7E75EBD592AFQ34915602-D9DF39F7-F00C-4BDA-99FC-848D2568FCA1Q35539305-652C9542-3A7C-4A76-A653-8AF91FD36F86Q37151932-9DD10FE7-CB64-42F9-B54A-895F584E7D2FQ37158159-65B8FE92-01C0-4519-A151-398DAEBFAC68Q37176470-8201E444-C46D-42D0-92E6-011423224801Q37199205-37EDD357-352B-47C0-84E2-D407F1345E6DQ37216146-D957B6AA-CC1A-47D9-8C04-750D99BF749EQ37273294-4005A2D4-6314-4C97-A250-3AF8E6FC5CBBQ37401599-5CAE94C6-E609-4EF1-BD69-25C0B22A4C78Q37451537-B38B45EC-AED6-41D5-A21A-FB69B5742BEBQ37510348-5A350FFF-94B3-4360-8B82-6CC11CB3FA7FQ37574913-ED8A6062-D14B-410E-BF7E-217C1D590789Q37629835-13CFBF9E-5AE4-47F8-9EA1-1735A5ACB0FDQ37695746-06D1AF16-21DA-4F82-8D54-12940A30D1ABQ37781702-2D27E7FA-F574-4BF2-9481-ABBC90F08DAFQ37802083-C664AB5F-9817-4059-815C-276556487C67Q37880858-83CAEF1C-5592-4911-A8B8-7592552D972EQ38010258-DBFF9440-ABD6-4776-A459-356FF4F089C4Q38045417-44894668-D2D7-4C2E-B5CC-69755A0E8510Q38048939-CB82460F-AA0D-4C2F-93B1-508DCC8055AAQ38121483-91B44E54-FA05-4D7D-84B1-3E8E4E594EA8Q38248810-DE62AEB7-F308-4918-9903-2BF89B479CB9
P2860
Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Adverse effects of combination ...... om randomized clinical trials.
@ast
Adverse effects of combination ...... om randomized clinical trials.
@en
type
label
Adverse effects of combination ...... om randomized clinical trials.
@ast
Adverse effects of combination ...... om randomized clinical trials.
@en
prefLabel
Adverse effects of combination ...... om randomized clinical trials.
@ast
Adverse effects of combination ...... om randomized clinical trials.
@en
P2093
P1476
Adverse effects of combination ...... om randomized clinical trials.
@en
P2093
Amir Kashani
Christopher O Phillips
Gary Francis
P304
P356
10.1001/ARCHINTE.167.18.1930
P407
P577
2007-10-01T00:00:00Z